Clinical Study of Ametinib Combined With Bevacizumab in First-line Treatment of Advanced NSCLC With EGFR-mutations.
Status:
Recruiting
Trial end date:
2025-12-01
Target enrollment:
Participant gender:
Summary
To explore the intracranial/extracranial ORR, PFS, QoL, safety, dynamic changes of tissue,
cerebrospinal fluid, and plasma DNA in patients with newly diagnosed advanced NSCLC with EGFR
mutation with/without brain metastasis given first-line treatment with almonertinib combined
with bevacizumab at the initial stage of treatment, during treatment and after drug
resistance, and the correlation between early clearance of sensitive mutations and survival.
Phase:
Phase 2
Details
Lead Sponsor:
The Second Affiliated Hospital of Shandong First Medical University